Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Oncology

Journal Scan / Research · April 09, 2015

Circulating Tumor DNA as a Biomarker for Treatment Failure in DLBCL

The Lancet Oncology

 

Additional Info

The Lancet Oncology
Circulating Tumour DNA and CT Monitoring in Patients With Untreated Diffuse Large B-Cell Lymphoma: A Correlative Biomarker Study
Lancet Oncol 2015 Apr 01;[EPub Ahead of Print], M Roschewski, K Dunleavy, S Pittaluga, M Moorhead, F Pepin, K Kong, M Shovlin, ES Jaffe, LM Staudt, C Lai, SM Steinberg, CC Chen, J Zheng, TD Willis, M Faham, WH Wilson

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading